Danthron
Based on 4 publication(s) in Google Scholar
Danthron is a natural product extracted from the traditional Chinese medicine Salvia miltiorrhiza Bunge. Danthron functions in regulating glucose and lipid metabolism by activating AMPK.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.22%
- CAS 番号: 117-10-2
- 分子式: C14H8O4
- 分子量:240.21
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- プロトコル
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Antiviral Compound Library
HY-L027
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-diabetic Compound Library
HY-L040
-
Oxygen Sensing Compound Library
HY-L045
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Food-Sourced Compound Library
HY-L094
-
Tumorigenesis-Related Compound Library
HY-L100
-
Anti-Cancer Natural Product Library
HY-L107
-
Antiviral Traditional Chinese Medicine Active Compound Library
HY-L113
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Pain-Related Compound Library
HY-L139
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Protease Inhibitor Library
HY-L147
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Cell Death Library
HY-L162
-
FDA-Approved Traditional Chinese Medicine Active Compound Library
HY-L163
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
RO5 Drug-like Natural Product Library
HY-L200
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Quinones Library
HY-L243
-
Tonifying Traditional Chinese Medicine Monomer Compound Library
HY-L246
-
Mass Spectrometry Natural Product Library
HY-L262
-
Drug Fragment Library
HY-L904
MedChemExpress（MCE）の使用を引用している文献 Danthron
More
Customer Validation & Images
-
Histological Imaging/Staining
-
RT-PCR
-
WB
-
In Vivo Efficacy Study
-
ELISA
AMPK アイソフォーム固有の製品をすべて表示
More
生物活性
|
AMPK |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HaCaT | IC50 |
>5 μM
Compound: 6q, danthron
|
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)
|
[PMID: 9371243] |
Danthron (0.1, 1, and 10 μM) dose-dependently promotes the phosphorylation of AMPK and acetyl-CoA carboxylase (ACC) in both HepG2 and C2C12 cells. Meanwhile, Danthron treatment significantly reduces the lipid synthesis related sterol regulatory element-binding protein 1c (SREBP1c) and fatty acid synthetase (FAS) gene expressions, and the total cholesterol (TC) and triglyceride (TG) levels. In addition, Danthron treatment efficiently increases glucose consumption. Danthron effectively reduces intracellular lipid contents and enhances glucose consumption in vitro via activation of AMPK signaling pathway. 10 μM Danthron/24 h is safe for HepG2 cells. With 80% confluence, HepG2 cells are incubated with Danthron (0.1-10 μM) in FBS-Free media for 8 h. Subsequently, cells are harvested for Western blot assay. Danthron increases the p-AMPK protein in a dose-dependent manner, and no changes in t-AMPK protein are observed[1]. Danthron inhibits 9-cis retinoic acid (9cRA)-induced retinoic X receptor α (RXRα) transactivation by IC50 at 0.11 μM. To further clarify the stoichimetric ratio of Danthron binding to RXRα-ligand-binding domain (LBD), isothermal titration calorimetry (ITC) experiment is performed. The KD value of Danthron binds to RXRα-LBD by ITC experiment is determined at 7.5 μM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 117-10-2
-
性状 Solid
-
分子量 240.21
-
分子式 C14H8O4
-
Color Brown to breen
-
SMILES
O=C1C2=C(C=CC=C2O)C(C3=CC=CC(O)=C13)=O
-
別名
Dantron; Chrysazin; 1,8-Dihydroxyanthraquinone; 8-ジヒドロキシアントラキノン
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
2025 Jul 4:S2090-1232(25)00504-1. PMID: 40617410 -
Biomed Pharmacother
Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2. [Abstract]2021 May;137:111344. PMID: 33581653
Danthron purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 May;137:111344. [Abstract]
Haematoxylin and eosin staining followed by quantitative analysis of steatosis score treated with Danthron (DAN) (10 mg/kg).
Danthron purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 May;137:111344. [Abstract]
Expression of genes responsible for fatty acid synthesis and uptake in liver were evaluated by q-RT-PCR treated with Danthron (DAN) (10 mg/kg).
Danthron purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 May;137:111344. [Abstract]
Expression of PPARα, ACOX1, and CPT1α at translational level was evaluated by Western blot treated with Danthron (DAN) (10 mg/kg).
Danthron purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 May;137:111344. [Abstract]
Rectal body temperature and finally change of temperature in HFD-fed mice with or without Danthron (10 mg/kg) treatment during cold tolerance test.
Danthron purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2021 May;137:111344. [Abstract]
Serum proinflammatory cytokines were assessed by the commercial kit treated with Danthron (DAN) (10 mg/kg).
-
Kaohsiung J Med Sci
LRP8 Regulates Lipid Metabolism to Stimulate Malignant Progression and Cisplatin Resistance in Bladder Cancer. [Abstract]2025 May 15:e70042. PMID: 40372166 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607
溶剤 & 溶解度
DMSO : 5 mg/mL (20.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (2.08 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (41.63 mM); Suspended solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
プロトコル
HepG2 cells are transfected with pGL3-ABCA1 promoter-luc or pGL3-ABCG1 promoter-luc and pRL-SV40 plasmids. At 6 h post-transfection, the cells are incubated with Danthron (0-20 μM), TO90 (2 μM) or DMSO for 24 h. Luciferase activity is measured using the Dual Luciferase Reporter Assay kit[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice[2]
C57/BL6 male mice are fed with a high fat diet for 3 months and treated with Danthron (5 mg/kg) or vehicle orally for 8 weeks. The animals are then fasted for 6 h and then given intraperitoneal injection of insulin at 1.5 units/kg. Blood samples are analyzed at 15, 30, 45, 60, 90, and 120 min using Accu-Chek active blood sugar test meter.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
純度とドキュメンテーション
-
データシート (282 KB)
-
SDS (558 KB)
- English - EN (558 KB)
- Français - FR (558 KB)
- Deutsch - DE (558 KB)
- Norwegian - NO (558 KB)
- Español - ES (558 KB)
- Swedish - SV (558 KB)
- Italian - IT (558 KB)
- Portuguese - PT (558 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Zhou R, et al. Danthron activates AMP-activated protein kinase and regulates lipid and glucose metabolism in vitro. Acta Pharmacol Sin. 2013 Aug;34(8):1061-9. [Content Brief]
[2]. Zhang H, et al. Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor. J Biol Chem. 2011 Jan 21;286(3):1868-75. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.1630 mL | 20.8151 mL | 41.6302 mL | 104.0756 mL |
| 5 mM | 0.8326 mL | 4.1630 mL | 8.3260 mL | 20.8151 mL | |
| 10 mM | 0.4163 mL | 2.0815 mL | 4.1630 mL | 10.4076 mL | |
| 15 mM | 0.2775 mL | 1.3877 mL | 2.7753 mL | 6.9384 mL | |
| 20 mM | 0.2082 mL | 1.0408 mL | 2.0815 mL | 5.2038 mL |
Powered by Bioz